To address this question, we assessed the potential role of the GALAD and BALAD-2 scores and their components AFP, AFP-L3, and DCP as biomarkers for transarterial or systemic treatment outcomes in a large European HCC patient cohort. Here, AFP is linked to hepatocellular carcinoma.